A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis

Gerontology

Volumn 49, Issue 3, 2003, Pages 177-184

  Banzhoff, Angelika ^a   Nacci, Pantaleo ^b   Podda, Audino ^b,c  

^a Clinical Research and Medical Affairs   (Germany)

^b Clin Research and Medical Affairs   (Italy)

^c Chiron Vaccines   (Italy)

Author keywords

Adjuvanted influenza vaccine; Chronic disease; Elderly

Indexed keywords

AGRIPAL S1; ALPHARIX; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

AGED; ANALYSIS OF VARIANCE; ANTIBODY TITER; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG SAFETY; ERYTHEMA; FEMALE; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALAISE; MALE; META ANALYSIS; MULTICENTER STUDY; MYALGIA; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN INDURATION;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY; INFLUENZA VACCINES; MALE; POLYSORBATES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SINGLE-BLIND METHOD; SQUALENE; TREATMENT OUTCOME;

EID: 0037261994     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069172     Document Type: Article

References (32)

1. Barker WH: Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-1978. Am J Public Health 1986;76:761-765.
2. Barker WH, Mullooly JP: Pneumonia and influenza deaths during epidemics: Implications for prevention. Arch Intern Med 1982;142:85-89.
3. Lui KJ, Kendal AP: Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987;77:712-716.
4. ACIP: Prevention and control of influenza. MMWR Recomm Rep 1997;46(RR-9):1-25.
5. Fiebach N, Beckett W: Prevention of respiratory infections in adults: Influenza and pneumococcal vaccines. Arch Intern Med 1994;154:2545-2557.
6. Beyer WE, Palache AM, Baljet M, Masurel N: Antibody induction by influenza vaccines in the elderly: A review of the literature. Vaccine 1989;7:385-394.
7. Arden NH, Patriarca PA, Kendal AP: Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes; in Kendal AP, Patriarca PA (eds): Options for the Control of Influenza. New York, Liss, 1986, pp 155-168.
8. Barker WH, Mullooly JP: Effectiveness of inactivated influenza vaccine among non-institutionalised elderly persons; in Kendal AP, Patriarca PA (eds): Options for the Control of Influenza. New York, Liss, 1986, pp 169-182.
9. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA: The efficacy of influenza vaccination in elderly individuals: A randomized double-blind placebo-controlled trial. JAMA 1994;272:1661-1665.
10. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA: The efficacy of influenza vaccine in elderly persons: A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-527.
11. Gross PA, Quinnan GV Jr, Weksler ME, Setia U, Douglas RG Jr: Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine 1989;7:303-308.
12. Strassburg MA, Greenland S, Sorvillo FJ, Lieb LE, Habel LA: Influenza in the elderly: Report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986;4:38-44.
13. Kilbourne ED: Inactivated influenza vaccines; in Plotkin A, Mortimer EA (eds): Vaccines. Philadelphia, Saunders, 1994, pp 565-581.
14. Clements ML, Stephens I: New and improved vaccines against influenza; in Levine MM, Woodrow GC, Kaper JB, Cobon GS (eds): New Generation Vaccines, ed 2. New York, Dekker, 1997, pp 545-570.
15. Keitel WA, Couch RB, Cate TR, Hess KR, Baxter B, Quarles JM, Atmar RL, Six HR: High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 1994;32:2468-2473.
16. Caplan ES, Hughes TP, O'Donnel S, Levine MM, Hornick RB: Reactogenicity and immunogenicity of parenteral monovalent influenza A/Victoria/3/75 (H3N2) virus vaccine in healthy adults. J Infect Dis 1977;136(suppl):484-490.
17. Freund J, Casals J, Hosmer EP: Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc Soc Exp Biol Med 1937;37:509-513.
18. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Benefraim S, Gupta CK: Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993;11:293-306.
19. Gupta RK, Siber GR: Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995;13:1263-1276.
20. Ott G, Barchfeld GL, Van Nest G: Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995;13:1557-1562.
21. Higgins DA, Carlson JR, Van Nest G: MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996;14:478-484.
22. Menegon T, Baldo V, Bonello C, Dalla Costa D, Di Tommaso A, Trivello R: Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 1999;15:573-576.
23. Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P: Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999;17:99-104.
24. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A: Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999;17:3094-3101.
25. Martin JT: Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals 1997;25:209-213.
26. Baldo V, Menegon T, Bonello C, Floreani A, Trivello R: Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001;19:3472-3475.
27. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, Podda A: Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001;17:135-140.
28. Dooley M, Goa KL: Adjuvanted influenza vaccine. Biodrugs 2000;14:61-69.
29. Palmer DF, Coleman MT, Dowdle WR, Schild CG: Haemagglutination inhibition test; in: Advanced Laboratory Techniques for Influenza Diagnosis. US Department of Health, Education, and Welfare 1979, pp 25-62.
30. Davies JR, Grilli EA: Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 1989;102:325-333.
31. Couch RB, Kasel JA: Immunity to influenza in man. Annu Rev Microbiol 1983;37:529-549.
32. Ghendon Y: Vaccination against influenza viruses: Current status. Adv Biotechnol Processes 1990;14:159-201.